^
    9d
    High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune Thrombocytopenia (clinicaltrials.gov)
    P3, N=86, Recruiting, Shandong University
    New P3 trial
    |
    Inokai (orelabrutinib) • dexamethasone
    11d
    Ultra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for Stage Ⅰ-Ⅱ MALT Lymphoma: A Prospective, Multicenter Phase Ⅱ Study (clinicaltrials.gov)
    P2, N=60, Recruiting, Zhejiang Cancer Hospital
    New P2 trial
    |
    Inokai (orelabrutinib)
    16d
    Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL) (clinicaltrials.gov)
    P2, N=32, Recruiting, Sun Yat-sen University | Trial completion date: Aug 2023 --> Aug 2028 | Trial primary completion date: Aug 2023 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    Rituxan (rituximab) • Inokai (orelabrutinib)
    17d
    Orelabrutinib combined with rituximab for the treatment of MZL with pss (ChiCTR2600121587)
    P2, N=12, The FIrst Affiliated Hospital, College of Medicine, Zhejiang University; The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • Inokai (orelabrutinib)
    17d
    Orelabrutinib Combined With Rituximab and Lenalidomide (OR2 Regimen) as First-line Treatment for Marginal Zone Lymphoma: a Multicenter Prospective Single Arm Trial (ChiCTR2600120773)
    P=N/A, N=36, The First Hospital of Jilin University; The First Hospital of Jilin University
    New trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • lenalidomide • Inokai (orelabrutinib)
    17d
    dexamethasone and orelabrutinib in newly diagnosed primary immune thrombocytopenia (ChiCTR2600120287)
    P=N/A, N=66, HenanCancerHospital; HenanCancerHospital
    New trial
    |
    Inokai (orelabrutinib) • dexamethasone
    19d
    Orelabrutinib and rituximab regimen combined with intravitreal methotrexate for treatment of primary vitreoretinal lymphoma: a case report and literature review. (PubMed, Front Oncol)
    Although agents such as lenalidomide and Bruton's tyrosine kinase(BTK) inhibitors have demonstrated efficacy in relapsed/refractory (R/R)PVRL, their role in treatment-naïve patients remains unclear. In conclusion, the combination of Orelabrutinib, rituximab, and intravitreal MTX is a feasible therapeutic strategy for PVRL. Our findings may contribute to a potential paradigm shift in the management of this rare disease.
    Journal
    |
    IL10 (Interleukin 10)
    |
    Rituxan (rituximab) • lenalidomide • methotrexate • Inokai (orelabrutinib)
    1m
    A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma (clinicaltrials.gov)
    P3, N=3, Completed, Beijing InnoCare Pharma Tech Co., Ltd. | Recruiting --> Completed | N=356 --> 3 | Trial completion date: Dec 2027 --> Jun 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Inokai (orelabrutinib)
    1m
    Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation (clinicaltrials.gov)
    P2, N=35, Recruiting, The First Affiliated Hospital of Soochow University
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    cyclophosphamide • Inokai (orelabrutinib) • Polivy (polatuzumab vedotin-piiq)
    2ms
    MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL (clinicaltrials.gov)
    P2, N=145, Recruiting, Ruijin Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    lenalidomide • Gazyva (obinutuzumab) • Inokai (orelabrutinib)
    2ms
    A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis (clinicaltrials.gov)
    P3, N=990, Recruiting, Zenas BioPharma (USA), LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Inokai (orelabrutinib)
    2ms
    Treatment of BTKi+Hi-CVP Regimen for Previously Untreated MZL (clinicaltrials.gov)
    P2, N=65, Active, not recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    cyclophosphamide • vincristine • Inokai (orelabrutinib) • Anruixi (zuberitamab)